https://scholars.lib.ntu.edu.tw/handle/123456789/641466
標題: | A novel trivalent non-Fc anti-CD3 Collabody preferentially induces Th1 cell apoptosis in vitro and long-lasting remission in recent-onset diabetic NOD mice | 作者: | Huang, Chuan-Chuan Sung, Hsiang-Hsuan Li, Hsiu-Chuan SHI-CHUEN MIAW Kung, John T Chou, Min-Yuan BETTY AN-YE WU-HSIEH |
關鍵字: | CD3; Collabody; Th1; Treg; apoptosis; trivalent antibody; type 1 diabetes | 公開日期: | 2023 | 出版社: | Frontiers Media SA | 卷: | 14 | 來源出版物: | Frontiers in immunology | 摘要: | Specific anti-CD3 treatment is deemed to be a promising therapy for allograft rejection and type 1 diabetes (T1D). Fc receptor (FcR) reduced-binding antibodies, by avoiding adverse effects of Fc and FcR interaction, have good therapeutic potential. We generated a trivalent anti-mouse-CD3 Collabody, h145CSA, by using a triplex-forming collagen-like peptide (Gly-Pro-Pro)10 to drive the trimerization of the Fab fragments. Exposure to h145CSA, but not its bivalent counterparts 145-2C11 and h145chIgGAA (FcR reduced-binding format), upregulates FasL expression on Th1 cells and causes Th1 cell apoptosis. Administration of h145CSA invokes minimal mitogenic effects in mice. The ability of multiple dosing of h145CSA to induce splenic CD4+ T-cell depletion is comparable to bivalent antibodies but is characterized by more rapid CD4+ T-cell recovery kinetics. h145CSA is more potent than h145chIgGAA in inducing long-lasting remission in recent-onset diabetic NOD mice. Its therapeutic effect is accompanied by a significantly lower percentage of CD4+IFNγ+ T cells and a higher Treg/Th1 ratio in pancreatic and mesenteric lymph nodes. The results of our study demonstrate that trivalent non-Fc anti-CD3 Collabody has the potential to be used in the treatment of T1D. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/641466 | ISSN: | 1664-3224 | DOI: | 10.3389/fimmu.2023.1201853 |
顯示於: | 免疫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。